Proximity Work in Family Medicine Groups : the Impact of Pharmacists

NCT02963636 | Completed

• 1 other identifier: 106238
• Study Type: interventional
• Target: 62
• Locations: 1 country
• Sites: 1

Brief Summary

The project objective is to evaluate the impact of the recent addition of pharmacists within family medicine groups (FMGs) on organizational and clinical parameters. The process by which changes occur and the level of pharmacists' activities will also be assessed. The ultimate goal of the project is the development of an accompanying guide to facilitate the work of the pharmacist in monitoring complex patients in primary care medical clinics.

Conditions

Health Services

Keywords

family medicine group; pharmacists; primary health care; pharmaceutical services; interprofessional relations

Outcome Measures

Primary Outcomes (1)

• Number of drug related problems

  3 to 6 months

Secondary Outcomes (3)

• Regimen complexity

  3 to 6 months

• Medication adherence

  3 to 6 months

• Quality of care provided by the clinical team (pharmacists, doctors, nurses, etc.)

  3 to 6 months

Study Arms (1)

Pharmacist clinical intervention

EXPERIMENTAL

Patients exposed to the pharmacist intervention

Other: Pharmacist clinical intervention

Interventions

Pharmacist clinical intervention OTHER

Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.

Pharmacist clinical intervention

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Willing to meet with the pharmacist and;
• Consuming drugs of four or more different pharmacological classes or having to take at least four doses per day and;
• aged 70 or over with at least two criteria of vulnerability or aged less than 70 with at least 3 criteria of vulnerability or had a recent loss of autonomy or in post- hospitalization with medication changes in the hospital.

You may not qualify if:

• None

Sponsors & Collaborators

• Laval University: lead
• McGill University: collaborator
• Fonds de la Recherche en Santé du Québec: collaborator
• Université de Sherbrooke: collaborator

Study Sites (1)

CIUSSS de la Capitale-Nationale

Québec, Quebec, Canada

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant professor

Study Record Dates

• First Submitted: February 17, 2016
• First Posted: November 15, 2016
• Study Start: August 1, 2015
• Primary Completion: April 1, 2016
• Study Completion: April 1, 2016
• Last Updated: November 15, 2016

Record last verified: 2016-11

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)